Jun Zhang, master
Xiamen University
12
0
6
N/A
0
12
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+16 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (12)
Showing 10 of 12 trials
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Ting Wu, Ph. D
Xiamen University
Shared therapeutic areas:
Worked with same sponsors:
Yuemei Hu, Bachelor
Jiangsu Provincial Centre for Disease Control and Prevention
Shared therapeutic areas:
Worked with same sponsors:
Long Sui, Ph.D.
Obstetrics & Gynecology Hospital of Fudan University
Shared therapeutic areas:
Worked with same sponsors:
Youlin Qiao, Ph.D
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Shared therapeutic areas:
Worked with same sponsors:
Xiaoqiang Liu, Ph.D.
Yunnan Center for Disease Control and Prevention
Shared therapeutic areas:
Worked with same sponsors:
Hong-xing Pan, master
Jiangsu Provincial Centre for Disease Control and Prevention
Shared therapeutic areas:
Worked with same sponsors:
Tianying Zhang, PhD
Xiamen University
Shared therapeutic areas:
Worked with same sponsors:
Hanqing He, PhD
Zhejiang Provincial Center for Disease Control and Prevention
Shared therapeutic areas:
Worked with same sponsors:
Feng-cai Zhu, master
Jiangsu Provincial Centre for Disease Control and Prevention
Shared therapeutic areas:
Worked with same sponsors:
Yue-mei Hu, Bachelor
Jiangsu Provincial Centre for Disease Control and Prevention
Shared therapeutic areas:
Worked with same sponsors:
Publications (0)
No publications found for this investigator.
Clinical Trials (12)
Showing 12 of 12 trials
A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese Males
Plateau Antibody Levels of a Recombinant (E.Coli) HPV Nonavalent Vaccine Versus Gardasil®9 in Young Women
An Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Years Old
Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) Versus Gardasil®9 in Healthy Females 18-26 Years of Age
Efficacy, Immunogenicity and Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
Immunogenicity Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine
Safety and Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine
Efficacy and Immunogenicity Study of Recombinant Human Papillomavirus Bivalent（Type 16/18 ）Vaccine
Dose-Ranging Study of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine
Childhood Infection and Immunity Longitudinal Cohort
All 12 trials loaded